Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS

Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, 68198, USA.
The Journal of Immunology (Impact Factor: 4.92). 08/2009; 183(1):661-9. DOI: 10.4049/jimmunol.0900274
Source: PubMed


Antiretroviral therapy (ART) shows variable blood-brain barrier penetration. This may affect the development of neurological complications of HIV infection. In attempts to attenuate viral growth for the nervous system, cell-based nanoformulations were developed with the focus on improving drug pharmacokinetics. We reasoned that ART carriage could be facilitated within blood-borne macrophages traveling across the blood-brain barrier. To test this idea, an HIV-1 encephalitis (HIVE) rodent model was used where HIV-1-infected human monocyte-derived macrophages were stereotactically injected into the subcortex of severe combined immunodeficient mice. ART was prepared using indinavir (IDV) nanoparticles (NP, nanoART) loaded into murine bone marrow macrophages (BMM, IDV-NP-BMM) after ex vivo cultivation. IDV-NP-BMM was administered i.v. to mice resulting in continuous IDV release for 14 days. Rhodamine-labeled IDV-NP was readily observed in areas of HIVE and specifically in brain subregions with active astrogliosis, microgliosis, and neuronal loss. IDV-NP-BMM treatment led to robust IDV levels and reduced HIV-1 replication in HIVE brain regions. We conclude that nanoART targeting to diseased brain through macrophage carriage is possible and can be considered in developmental therapeutics for HIV-associated neurological disease.

Download full-text


Available from: Christopher Destache,
  • Source
    • "Notwithstanding, he noted, as did several other speakers on the day, that the hypothesis that the CNS serves as a reservoir site for HIV remains to be conclusively proven. Were this found to be the case, the issue of achieving effective antiretroviral CNS penetrance would be important and Dr Margolis highlighted some research directed towards providing cART via nanoformulations to enhance their CNS levels (Dou et al. 2009). The issue of establishing an ideal model to study HIV persistence in different tissues including the brain was discussed (Dinoso et al. 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: On 18 July 2014, the National Institute of Mental Health in collaboration with ViiV Health Care and Boehringer Ingelheim supported a symposium on HIV eradication and what it meant for the brain. The symposium was an affiliated event to the 20th International AIDS Conference. The meeting was held in Melbourne, Australia, and brought together investigators currently working on HIV eradication together with investigators who are working on the neurological complications of HIV. The purpose of the meeting was to bring the two fields of HIV eradication and HIV neurology together to foster dialogue and cross talk to move the eradication field forward in the context of issues relating to the brain as a potential reservoir of HIV. The outcomes of the symposium were that there was substantive but not definitive evidence for the brain as an HIV reservoir that will provide a challenge to HIV eradication. Secondly, the brain as a clinically significant reservoir for HIV is not necessarily present in all patients. Consequently, there is an urgent need for the development of biomarkers to identify and quantify the HIV reservoir in the brain. Lastly, when designing and developing eradication strategies, it is critical that approaches to target the brain reservoir be included.
    Journal of NeuroVirology 03/2015; 21(3). DOI:10.1007/s13365-015-0322-6 · 2.60 Impact Factor
  • Source
    • "Macrophages have been used to deliver various cargoes aimed at reducing HIV replication in the brain [10], preventing tumor growth [11], targeting brain metastases [12], and reducing brain inflammation in a Parkinson's disease model by providing neuroprotective capabilities [13]. While related, monocytes are distinct from macrophages, and only recently have monocytes been investigated as vehicles to deliver therapeutic agents to pathological tissues [14]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Targeted delivery of drugs and imaging agents to inflamed tissues, as in the cases of cancer, Alzheimer's disease, Parkinson's disease, and arthritis, represents one of the major challenges in drug delivery. Monocytes possess a unique ability to target and penetrate into sites of inflammation. Here, we describe a broad approach to take advantage of the natural ability of monocytes to target and deliver flat polymeric particles ("Cellular Backpacks") to inflamed tissues. Cellular backpacks attach strongly to the surface of monocytes but do not undergo phagocytosis due to backpack's size, disk-like shape and flexibility. Following attachment of backpacks, monocytes retain important cellular functions including transmigration through and endothelial monolayer and differentiation into macrophages. In two separate in vivo inflammation models, backpack-laden monocytes exhibit increased targeting to inflamed tissues. Cellular backpacks, and their abilities to attach to monocytes without impairing monocyte functions and 'hitchhike' to a variety of inflamed tissues, offer a new platform for both cell-mediated therapies and broad targeting of inflamed tissues. Copyright © 2014. Published by Elsevier B.V.
    Journal of Controlled Release 12/2014; 199. DOI:10.1016/j.jconrel.2014.11.027 · 7.71 Impact Factor
  • Source
    • "Additionally, these immune cells possess the ability to readily migrate across the BBB or at least transfer their drug content to endothelial cells at the BBB, as recently shown in vitro (Figure 5).106 The previous possibilities have been systematically explored by investigators at the Nebraska Medical Center, Omaha, NE, USA.103–109 Drug incorporation into cells was performed by simply incubating cells with particles in culture media for 8–12 hours, followed by cell washing and removal of free drug. Researchers observed that nanoformulated indinavir could be delivered into the brain of an HIV-1 encephalitis rodent model up to around 20-fold higher levels when incorporated into bone marrow-derived macrophages after a single dose administered intravenously.109 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Antiretroviral drug therapy plays a cornerstone role in the treatment of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome patients. Despite obvious advances over the past 3 decades, new approaches toward improved management of infected individuals are still required. Drug distribution to the central nervous system (CNS) is required in order to limit and control viral infection, but the presence of natural barrier structures, in particular the blood-brain barrier, strongly limits the perfusion of anti-HIV compounds into this anatomical site. Nanotechnology-based approaches may help providing solutions for antiretroviral drug delivery to the CNS by potentially prolonging systemic drug circulation, increasing the crossing and reducing the efflux of active compounds at the blood-brain barrier, and providing cell/tissue-targeting and intracellular drug delivery. After an initial overview on the basic features of HIV infection of the CNS and barriers to active compound delivery to this anatomical site, this review focuses on recent strategies based on antiretroviral drug-loaded solid nanoparticles and drug nanosuspensions for the potential management of HIV infection of the CNS.
    International Journal of Nanomedicine 04/2014; 9(1):1757-1769. DOI:10.2147/IJN.S45886 · 4.38 Impact Factor
Show more